Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
about
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dacomitinib (PF-00299804), a s ...... us endometrial cancer in vitro
@en
type
label
Dacomitinib (PF-00299804), a s ...... us endometrial cancer in vitro
@en
prefLabel
Dacomitinib (PF-00299804), a s ...... us endometrial cancer in vitro
@en
P2093
P2860
P1433
P1476
Dacomitinib (PF-00299804), a s ...... us endometrial cancer in vitro
@en
P2093
Alessandro D Santin
Beatrice Bussi
Carlton L Schwab
Dan-Arin Silasi
Diana P English
Elena Ratner
Emiliano Cocco
Federica Predolini
Jonathan Black
Liancheng Zhu
P2860
P2888
P304
P356
10.1007/S13277-015-3218-4
P577
2015-02-11T00:00:00Z
P5875
P6179
1011187307